FDA Inspection
Regeneron Pharmaceuticals IncRegeneron Pharmaceuticals Inc – FDA Inspection, Mar 22, 2024
Record Details
This FDA Inspection record concerns Regeneron Pharmaceuticals Inc, with an inspection on March 22, 2024, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · 7df63927-1928-4995-8887-1541aa1d5420
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1230565
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
Other FDA inspections of Regeneron Pharmaceuticals Inc
12| Date | Classification | Office | Project area |
|---|---|---|---|
| February 16, 2024 | Not classified | New York District Office | |
| October 25, 2021 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 18, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| June 8, 2018 | Not classified | New York District Office | |
| October 5, 2017 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Regeneron Pharmaceuticals Inc
- FDA Inspection 1239760 - 2024-02-16
- FDA Inspection 1155063 - 2021-10-25
- FDA Inspection 1106821 - 2019-10-18
- FDA Inspection 1059234 - 2018-06-08
- FDA Inspection 1030807 - 2017-10-05
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.